Document is current
Any future updates will be listed below
-
Authors
Bresee, Lauren C.
Lamont, Nicole
Ocampo, Wrechelle
Holroyd-Leduc, Jayna
Sabuda, Deana
Leal, Jenine
Dalton, Bruce
Kaufman, Jaime
Missaghi, Bayan
Kim, Joseph
Larios, Oscar E.
Henderson, Elizabeth
Raman, Maitreyi
Fletcher, Jared R.
Faris, Peter
Kraft, Scott
Shen, Ye
Louie, Thomas
Conly, John M. https://orcid.org/0000-0002-3348-0157
-
Funding
Funding for this research was provided by:
Alberta Innovates’ Partnership for Research and Innovation in the Health System (Alberta Innovates’ Partnership for Research and Innovation in the Health System (PRIHS))
- License Information
-
More Information
Article History
Received: 20 January 2023
Accepted: 17 November 2023
First Online: 11 December 2023
Declarations
:
: Ethics approval to conduct this study was obtained from the Conjoint Health Research Ethics Board at the University of Calgary (REB16-1834). Specifically, a waiver of individual consent for in-hospital administration of probiotics to the patients in the pragmatic, quasi-experimental, stepped wedge, cluster randomized trial (Prevent CDI-55 +), was granted. However, patients received an information package upon Bio-K + administration containing information on the initiative, use of probiotics, their effectiveness in preventing CDI, and their safety. In addition, a waiver of consent was also granted for health information access, consistent with the provisions of the Health Information Act of Alberta. Consent was obtained at the time of agreement to participate by individuals in the focus groups. The information sheet that was provided to all focus group participants is provided in Appendix. The different facets of this study adhered to the most recent version of the Declaration of Helsinki.
: Not applicable.
: TL and OEL receive industry research funding from Finch Therapeutics, Rebiotix Inc, Crestone Inc, Artugen Therapeutics, Seres Therapeutics, ImmuniMed Inc, MGB Biopharma, Summit Therapeutics and Vedanta Biosciences for clinical trials of C. <i>difficile</i> therapeutics. All other authors had no competing interests to declare.
